Clinical trials: Breast Cancer
Breast Cancer
The Effect of Training Given by Mobile Application to Women Undergoing Breast Surgery
In a metanalysis study examining the effects of mobile health applications on the quality of life and psychological outcomes of patients with breast cancer, it was concluded that the quality of life increased, the level of…
- Trial name
- NCT04914780
- Testing
- Education
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people
- Sponsor
- KTO Karatay University
HER2-positive Breast Cancer
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
- Trial name
- NCT06330012
- Testing
- GeoMx data analysis with clinical outcome
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Breast Neoplasm Malignant Female
Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients
PRO-COM Project: Randomized-controlled study evaluating the impact of electronic patient reported outcome (ePRO) surveys on patient-physician communication and quality of life in patients with advanced breast cancer
- Trial name
- NCT03525990
- Testing
- Questionnaires
- Where
- 2 sites in Austria
- Volunteers
- 62 people
- Sponsor
- Dr. Vera Trommet
Breast Cancer, Chemotherapy Effect
Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer
Introduction: Neoadjuvant chemotherapy (NACT) has been the standard therapy for treating patients with locally advanced breast cancer (LABC). Doxorubicin-based regimen showed a clinical response for 70-80%.
- Trial name
- NCT04418089
- Testing
- Simvastatin 40mg
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Indonesia
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Breast Carcinoma
Improving The Breast Cancer Care Delivery Model for Sex and Gender Minority Survivors, Intended for SGM Study
This study evaluates Improving the Breast Cancer Care Delivery Model for Sex and Gender Minority (INTENDED for SGM) in identifying the patient, support person and provider barriers to quality care in SGM breast/chest cancer…
- Trial name
- NCT06205394
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Neoplasms (Cancer / Tumors), Colorectal Neoplasms
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment
Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typically using immunohistochemistry or sequencing.
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms
- Trial name
- FATHOM (NCT07814872)
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer, Cancer
Vinorelbine and XR9576 to Treat Cancer
Tumor resistance to anti-cancer drugs is a major problem in cancer treatment. Studies have found that a protein (P-glycoprotein) on some cancer cells pumps chemotherapy drugs out of the cells, reducing treatment effectiveness.
- Conditions
- Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00001944
- Testing
- Vinorelbine, XR9576
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer.
- Trial name
- NCT02718144
- Testing
- Estetrol
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Pantarhei Oncology B.V.
Breast Cancer
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
- Trial name
- FIONA (NCT00880711)
- Where
- 13 sites in Austria
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Breast Cancer
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like.
- Trial name
- Triple-B (NCT01898117)
- Testing
- Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel
- Where
- 49 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer, Menopause
Comparison of the Efficacy and Tolerability of Femal Versus Placebo
Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.
- Trial name
- NCT05762042
- Testing
- dietary supplement
- Where
- 2 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Azienda Ospedaliera Ordine Mauriziano di Torino
ERBB2, Breast Cancer
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
The aim of this study is to analyze cases of human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) of the last 10 years at the University Hospital of Zurich to assess the efficacy of the treatment…
- Conditions
- ERBB2, Breast Cancer, Metastatic Neoplasm
- Trial name
- NCT02560311
- Testing
- observation
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Breast Cancer
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00126464
- Testing
- fulvestrant, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer, Cognitive Dysfunction
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
Investigator propose the first French randomized comparative study to assess the efficacy of a remotely supervised online cognitive stimulation program, compared to an unsupervised online cognitive exercise intervention, in…
- Trial name
- COG STIM 2 (NCT06027632)
- Testing
- Cognitive exercises with supervision, Cognitive exercises without supervision
- Where
- 25 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Francois Baclesse
Seroma Following Procedure
The Effect of Octreotide on Wound Drainage After Mastectomy
Patients who had mastectomy for breast cancer usually have drainage of some fluid from the site of surgery. This could be prolonged and may lead to other negative consequences after surgery.
- Trial name
- NCT05682209
- Testing
- Octreotide Injection, Sterile water
- Where
- Nigeria
- Volunteers
- 41 people
- Sponsor
- Ikechukwu Bartholomew Ulasi
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.